CatalystFDA/Bio

Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care

FDA clearance for a novel Alzheimer's blood biomarker expands Roche's diagnostic market access.

What changed

FDA clearance for a novel Alzheimer's blood biomarker expands Roche's diagnostic market access.

Why it matters

FDA clearance for a novel Alzheimer's blood biomarker expands Roche's diagnostic market access. — impact context not separately stored; see What changed.

Sources

eodhd